Biomarkers of Brain Injury in Critically-Ill Children on Extracorporeal Membrane Oxygenation (ECMO)

体外膜氧合 (ECMO) 危重儿童脑损伤的生物标志物

• 批准号: 10545733
• 负责人: Melania Maria Bembea
• 金额: $ 59.91万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10545733
• 关键词: Acute; Adaptive Behaviors; Adult; Astrocytes; Benchmarking; Biological Markers; Brain; Brain Injuries; Brain Ischemia; Brain hemorrhage; Brain-Derived Neurotrophic Factor; CCL2 gene; Caring; Cell Death; Cessation of life; Child; Childhood; Choline; Classification; Clinical; Clinical Chemistry; Clinical Research; Clinical Trials; Complement; Creatine; Critical Illness; Critically ill children; Data; Development; Diagnosis; Encephalitis; Exposure to; Extracorporeal Membrane Oxygenation; Failure; Feedback; Fright; Future; Glial Fibrillary Acidic Protein; Glutamates; Goals; Growth Associated Protein 43; Health; Heart Arrest; Heart failure; Hospitals; IL8 gene; Impairment; Inflammation; Inflammatory; Infrastructure; Injury; Intensive Care Units; Interleukin-1 beta; Interleukin-10; Interleukin-6; Intervention; Ischemia; Kynurenine; Life; Lipids; Longitudinal cohort; Measures; Metabolic; Methods; Monitor; N-acetylaspartate; Necrosis; Nervous System Trauma; Nested Case-Control Study; Neurologic; Neurological outcome; Neurons; Observational Study; Organ; Outcome; Pathology; Pathway interactions; Patients; Pediatric Hospitals; Performance; Phase; Plasma; Proteins; Public Health Schools; Recovery; Refractory; Research; Research Infrastructure; Resources; Risk; Risk Factors; Sampling; Schools; Shock; Survivors; TNF gene; Techniques; Technology; Testing; Time; Training; Treatment Efficacy; UCHL1 gene; alpha synuclein; biomarker panel; blood-brain barrier disruption; brain magnetic resonance imaging; circulating biomarkers; cohort; cost; cytokine; disability; experience; high risk; imaging biomarker; improved; inflammatory marker; insight; interest; lung failure; modifiable risk; mortality; mortality risk; myoinositol; neurogranin; neuroimaging; neuroinflammation; neurological recovery; neuroprotection; novel; pre-clinical; prospective; response; stem; survival outcome; telencephalin

PROJECT SUMMARY With advances in technology, the use of extracorporeal membrane oxygenation (ECMO) for severe refractory heart and lung failure has quadrupled in children and increased tenfold in adults in the last 15 years. ECMO is life-saving, but costly, resource-intensive, and high-risk. Up to 30% of pediatric ECMO patients develop neurologic injury. Mortality increases by 89% if injury occurs, and 10%-60% of survivors have clinically important neurologic disability that impairs normal development and school performance. We currently lack the ability to accurately stratify children at risk for death or disability, and to diagnose injury in subclinical phase, thus missing the window for potential neuroprotective interventions. The overall goal of this research is to develop and refine a brain injury multimarker panel for accurate neurologic monitoring at the bedside and early classification of mortality and disability outcomes that will allow real-time neuroprotective interventions, with the ultimate goal to improve neurodevelopmental outcomes of these critically ill children. We hypothesize that circulating markers of brain injury and inflammation can assist in diagnosing difficult-to-image neurologic injury; provide real-time feedback to neuroprotective or potentially deleterious interventions in the intensive care unit; identify patients at risk for long-term neurologic disability; and serve as entry criteria and benchmarks of therapeutic efficacy in future interventional clinical trials through a more refined approach than is currently possible. Based on preliminary data from single and two-center studies, we propose a multicenter prospective observational study (9 centers, 225 subjects) that will seek to determine the association between plasma and imaging markers of brain injury and inflammation during ECMO and short and long-term survival and neurologic outcomes of critically-ill children who require extracorporeal support. Using targeted and discovery approaches, we will address our overall goal in the following specific aims, with the support and well-established research infrastructure of the Johns Hopkins Bloomberg School of Public Health, Pediatric Neurocritical Care Research Group and the Kennedy Krieger Institute: (1) Determine if circulating levels of brain injury markers during ECMO and brain MRI abnormalities at 2 weeks after ECMO are associated with survival at 18 months after ECMO with a score ≥85 on the Vineland Adaptive Behavior Scales, third edition (VABS-III); (2) Determine whether the presence and degree of inflammation during ECMO and markers of neuroinflammation on brain MRS at 2 weeks after ECMO are associated with survival at 18 months after ECMO with a score ≥85 on VABS-III; (3) Determine whether metabolic and lipid neuroinflammatory pathways will distinguish between at-risk for, acute, and recovery phases of neurologic injury during ECMO.

项目摘要 随着技术的进步，使用体外膜肺氧合（ECMO）治疗严重难治性肺损伤， 在过去的15年里，儿童的心脏和肺衰竭增加了四倍，成人增加了十倍。ECMO是 拯救生命，但成本高，资源密集，风险高。多达30%的儿科ECMO患者会出现 神经损伤如果发生损伤，死亡率增加89%，10%-60%的幸存者具有临床重要的 损害正常发育和学校表现的神经系统残疾。我们目前缺乏能力， 准确地对有死亡或残疾风险的儿童进行分层，并在亚临床阶段诊断损伤， 潜在的神经保护干预的窗口。本研究的总体目标是开发和完善 脑损伤多标记物面板用于床旁准确的神经病学监测和早期分类 死亡率和残疾结果，这将允许实时神经保护干预，最终目标是 改善这些重症儿童的神经发育结果。我们假设循环中的 脑损伤和炎症可以帮助诊断难以成像的神经损伤;提供实时 对重症监护室中的神经保护或潜在有害干预的反馈; 长期神经功能障碍的风险;并作为治疗有效性的入选标准和基准， 未来的干预性临床试验，通过更精细的方法比目前可能的。基于 根据单中心和双中心研究的初步数据，我们提出了一项多中心前瞻性观察研究 （9个中心，225名受试者），将寻求确定血浆和成像标记物之间的关联， ECMO期间的脑损伤和炎症以及ECMO的短期和长期生存率和神经学结局 需要体外支持的危重儿童。使用目标和发现方法，我们将 在以下具体目标中实现我们的总体目标，并得到支持和完善的研究 约翰霍普金斯彭博公共卫生学院儿科神经重症监护研究基础设施 研究小组和肯尼迪克里格研究所：（1）确定ECMO期间脑损伤标志物的循环水平 ECMO后2周的脑MRI异常与ECMO后18个月的生存率相关， 葡萄园适应行为量表第三版（VABS-III）评分≥85;（2）确定是否 ECMO期间炎症的存在和程度以及2周时脑MRS上的神经炎症标志物 ECMO后VABS-III评分≥85的患者与ECMO后18个月的生存率相关;（3）确定 代谢和脂质神经炎性通路是否将区分处于危险中、急性和恢复 ECMO期间的神经损伤阶段。

项目成果

The brain in pediatric critical care: unique aspects of assessment, monitoring, investigations, and follow-up.

• DOI: 10.1007/s00134-022-06683-4
• 发表时间: 2022-05
• 期刊: INTENSIVE CARE MEDICINE
• 影响因子: 38.9
• 作者: Brown, Kate L.;Agrawal, Shruti;Kirschen, Matthew P.;Traube, Chani;Topjian, Alexis;Pressler, Ronit;Hahn, Cecil D.;Scholefield, Barnaby R.;Kanthimathinathan, Hari Krishnan;Hoskote, Aparna;D'Arco, Felice;Bembea, Melania;Manning, Joseph C.;Hunfeld, Maayke;Buysse, Corinne;Tasker, Robert C.
• 通讯作者: Tasker, Robert C.

Cardiovascular Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference.

• DOI: 10.1542/peds.2021-052888f
• 发表时间: 2022-01-01
• 期刊: PEDIATRICS
• 影响因子: 8
• 作者: Alexander, Peta M. A.;Checchia, Paul A.;Ryerson, Lindsay M.;Bohn, Desmond;Eckerle, Michelle;Gaies, Michael;Laussen, Peter;Jeffries, Howard;Thiagarajan, Ravi R.;Shekerdemian, Lara;Bembea, Melania M.;Zimmerman, Jerry J.;Kissoon, Niranjan
• 通讯作者: Kissoon, Niranjan

Neuromonitoring During ECMO Support in Children.

儿童 ECMO 支持期间的神经监测。

• DOI: 10.1007/s12028-023-01675-8
• 发表时间: 2023
• 期刊: Neurocritical care
• 影响因子: 3.5
• 作者: Felling,RyanJ;Kamerkar,Asavari;Friedman,MatthewL;Said,AhmedS;LaRovere,KerriL;Bell,MichaelJ;Bembea,MelaniaM
• 通讯作者: Bembea,MelaniaM

Scoring Systems for Organ Dysfunction and Multiple Organ Dysfunction: The PODIUM Consensus Conference.

• DOI: 10.1542/peds.2021-052888d
• 发表时间: 2022-01-01
• 期刊: PEDIATRICS
• 影响因子: 8
• 作者: Schlapbach, Luregn J.;Weiss, Scott L.;Bembea, Melania M.;Carcillo, Joseph A.;Leclerc, Francis;Leteurtre, Stephane;Tissieres, Pierre;Wynn, James L.;Zimmerman, Jerry;Lacroix, Jacques
• 通讯作者: Lacroix, Jacques

Impact of red blood cell transfusion on regional cerebral oxygen saturation during pediatric ECMO.

儿科 ECMO 期间红细胞输注对局部脑氧饱和度的影响。

• DOI: 10.1111/trf.17317
• 发表时间: 2023
• 期刊: Transfusion
• 影响因子: 2.9
• 作者: Garcia,AlejandroV;Velez,AnaKaren;Surma,Victoria;Jager,LeahR;Bembea,MelaniaM
• 通讯作者: Bembea,MelaniaM